secwatch.observer — SEC 8-K summary
======================================

Issuer:     Annovis Bio, Inc. (ANVS)
CIK:        0001477845
Form:       8-K
Filed at:   2026-05-15T20:00:58+00:00
Accession:  0001104659-26-062451
Event type: earnings
Sentiment:  neutral
Materiality: 0.70
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Annovis Bio Q1 net loss $0.63/sh; AD Phase 3 85% enrolled; NDA planned early 2027
--------------------------------------------------------------------------------

- Net loss per share $0.63 (vs $0.32 in Q1 2025); R&D spend $16.7M (up from $5.0M).
- Cash $14.2M at Mar 31, 2026; $10M April offering not included; 28.5M shares outstanding.
- Phase 3 AD trial 85% enrolled, full enrollment on track summer 2026; DSMB safety recommendation positive.
- PD OLE study 40% enrolled; NDA for buntanetap symptomatic AD treatment expected early 2027.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1477845/000110465926062451/0001104659-26-062451-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1477845/000110465926062451/tm2614822d1_8k.htm
  HTML page:      https://secwatch.observer/filing/0001104659-26-062451

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer